

1 **In-Hospital and Long-Term Outcomes in Spontaneous Coronary Artery Dissection**
2 **(SCAD) with Concurrent Cardiac Arrest: A Systematic Review and Meta-Analysis**

3 **Short title: Outcomes in Spontaneous Coronary Artery Dissection (SCAD) with**
4 **Concurrent Cardiac Arrest**

5 Omar Baqal, MBBS^{1*}, Suganya A. Karikalan, MBBS^{1,2}, Elfatih A. Hasabo, MBBS^{3,4}, Haseeb Tareen, MBBS^{1,5},
6 Pragyat Futela, MBBS^{6,7}, Rakhtan K. Qasba, MBBS⁸, Areez Shafqat, MBBS⁹, Ruman K. Qasba, MBBS¹⁰,
7 Sharonne N. Hayes, MD, FACC, FAHA⁶, Marysia S. Tweet, MD, MS⁶, Hicham Z. El Masry, MD, FHRS¹, Kwan S.
8 Lee, MBBCh, MD, FSCAI¹, Win-Kuang Shen, MD, FHRS¹, Dan Sorajja, MD, FHRS¹

9 ¹Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona, USA

10 ²CHRISTUS Good Shepherd Medical Center, Longview, Texas, USA

11 ³CORRIB Research Centre for Advanced Imaging and Core Laboratory, Clinical Science Institute, University of
12 Galway, Galway, Ireland

13 ⁴Discipline of Cardiology, Saolta Healthcare Group, Health Service Executive, Galway University Hospital,
14 Galway, Ireland

15 ⁵Henry Ford Jackson Hospital, Jackson, Michigan, USA

16 ⁶Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA

17 ⁷MetroHealth Medical Center, Cleveland, Ohio, USA

18 ⁸Green Life Medical College and Hospital, Dhaka, Bangladesh

19 ⁹College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

20 ¹⁰Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu & Kashmir, India

21

22 *** Corresponding author:**

23 Omar Baqal, MBBS

24 Department of Cardiovascular Medicine,

25 Mayo Clinic, Phoenix, Arizona 85054, USA

26 Baqal.omar@mayo.edu

27

28 **Disclosures:** Dr. Marysia Tweet is supported by a grant from the National Heart, Lung, and Blood Institute,
29 NIH K23H155506. The Mayo Clinic “Virtual” Multicenter SCAD Registry receives support from SCAD Research,
30 Inc.

31 **Acknowledgements:** Graphical abstract created with BioRender. Blood vessel image in graphical abstract used with
32 permission of Mayo Foundation for Medical Education and Research, all rights reserved.

33 **Funding:** None

34

35 **Text proper:** 3604 words

36 **Total word count:** 5258 (including Title page, acknowledgements, keywords, table, figure legends, main text and
37 references)

38 **Number of references:** 42

39

40 **Key words:** spontaneous coronary artery dissection, cardiac arrest, ventricular arrhythmia, ventricular fibrillation,
41 ventricular tachycardia, sudden cardiac death, myocardial infarction, defibrillation

42

43

44

45

46

47

48

49 **Abstract**

50 **Background**

51 Spontaneous coronary artery dissection (SCAD) is increasingly recognized as an important cause of myocardial
52 infarction (MI). However, our understanding of clinical characteristics that predispose patients to worse outcomes,
53 such as concurrent sudden cardiac arrest (CA), remains limited.

54 **Objective**

55 We performed a systematic review and meta-analysis of studies assessing clinical outcomes among SCAD patients
56 with concurrent CA.

57 **Methods**

58 This study was performed according to PRISMA guidelines. PubMed, Cochrane, and Scopus were systematically
59 searched using relevant search terms, such as “Spontaneous Coronary Artery Dissection”, “Ventricular
60 Tachycardia”, “Ventricular Fibrillation”, “Sudden Cardiac Death” and “Cardiac Arrest”. The search was conducted
61 from database inception to July 2024. Studies assessing the clinical outcomes of SCAD patients with concurrent CA
62 were included. RevMan 5.4 was used for meta-analysis.


63 **Results**

64 After removal of duplicates, 269 studies underwent screening, out of which 10 studies were included (n= 3978
65 patients, 357 with CA). In-hospital mortality, post-discharge mortality, recurrent MI and recurrent SCAD occurred
66 in 20%, 3%, 12% and 9% of SCAD patients with CA, respectively. When compared to SCAD patients without CA,
67 SCAD patients with CA were at significantly higher risk of in-hospital mortality (RR = 6.75, 95% CI [4.50, 10.14],
68 $I^2=0\%$), post-discharge mortality (RR = 5.86, 95% CI [1.72, 19.91], $I^2=0\%$), recurrent MI (RR =3.31, 95% CI [2.03,
69 5.39], $I^2=56\%$), recurrent SCAD (RR = 1.91, 95% CI [1.11, 3.27], $I^2=43\%$), acute heart failure (RR = 4.82, 95% CI
70 [3.22, 7.20], $I^2=42\%$), and cardiogenic shock (RR = 6.11, 95% CI [4.07, 9.19], $I^2=64\%$). Out of a pooled 24
71 implanted cardiac defibrillators (ICDs) and 11 wearable cardiac defibrillators (WCDs), there was only one
72 appropriate and one inappropriate ICD discharge recorded over the follow-up period.

73 **Conclusion**

74 In this cohort, SCAD with concurrent CA was associated with worse in-hospital and long-term outcomes including
75 in-hospital and post-discharge mortality, acute heart failure, and recurrent MI and SCAD. There was a low long-
76 term rate of administered defibrillator therapies among patients discharged from the hospital with an ICD or WCD.
77 Further research is needed to better delineate optimal management approaches toward this high-risk patient
78 population, including secondary prevention of sudden cardiac death.

79 Graphical abstract



80

81

82

83

84

85

86 **Introduction**

87 Spontaneous coronary artery dissection (SCAD) is a form of acute coronary syndrome (ACS) characterized by the
88 non-traumatic, non-iatrogenic intimal tear or separation of the coronary arterial tunica intima and media by an
89 intramural hematoma^{1,2}. This is often in the setting of a pre-existing arteriopathy weakening the arterial wall, with
90 additional precipitating emotional or physical stressors that incite the dissection³⁻⁶. Although its true prevalence is
91 unknown, the increasing use of advanced intracoronary imaging techniques and greater awareness has led to SCAD
92 being recognized as an important etiology of ACS. A disease of young-to-middle aged women, SCAD is responsible
93 for 24-35% of cases of ACS in women < 60 years of age⁷. Predisposing conditions to SCAD include fibromuscular
94 dysplasia, inheritable connective tissue diseases, and pregnant/postpartum status^{3,4}. The most common presentation
95 of SCAD is non-ST segment elevation myocardial infarction (NSTEMI) followed by STEMI, with an estimated 10-
96 20% presenting with cardiac arrest⁸.

97 The presence of ventricular arrhythmia (VA) has been reported in 3-13% of patients with SCAD and has been
98 associated with worse in-hospital and long-term outcomes, including mortality and MACE⁹. Risk stratification for
99 sudden cardiac death (SCD) in SCAD remains poorly explored, and guidelines are unclear on whether or not to
100 pursue ICD implantation in patients with a reversible cause of SCD⁹. Additionally, data remains scarce pertaining to
101 optimal revascularization strategies, timing of ICD implantation, long-term ICD outcomes, and role of wearable
102 cardiac defibrillators (WCDs) at hospital discharge in patients with SCAD and concurrent CA.

103 To consolidate published literature on the topic, we performed a systematic review to explore the impact of
104 concurrent CA in SCAD on in-hospital and long-term clinical outcomes.

105 **Methods**

106 This meta-analysis was carried out and reported per the Preferred Reporting Items for Systematic Reviews and
107 Meta-analyses (PRISMA)¹⁰. The study was registered on PROSPERO with registration ID CRD42024511286.

108 **Literature search**

109 We performed a search for studies reporting outcomes of people with SCAD complicated by CA, which included
110 VT/VF, pulseless electrical activity (PEA) and asystole. Searches were performed on PubMed/MEDLINE,

111 Cochrane, and Scopus using keywords and standardized index terms, such as “Spontaneous Coronary Artery
112 Dissection”, “Ventricular Tachycardia”, “Ventricular Fibrillation”, “Sudden Cardiac Death” and “Cardiac Arrest”.
113 The search was conducted from date of database establishment to July 2024.

114 **Inclusion and exclusion criteria for identification of studies**

115 Articles were considered eligible for inclusion if they were written in English, were peer-reviewed observational
116 studies or randomized clinical trials; included adults ≥ 18 years of age, reported on outcomes of patients with SCAD
117 and concurrent CA, and included information on hospital follow-up and longer. Studies that did not report on the
118 distinct outcomes of SCAD with CA, included participants under 18 years of age, or those with no hospital or post-
119 discharge follow-up were excluded. We also excluded meta-analyses, systematic reviews, case reports, abstracts,
120 editorials, commentaries, and letters to the editor.

121 **Data screening**

122 Two reviewers (SK and HT) screened the title and abstracts of all retrieved studies using the pre-defined selection
123 criteria. The full texts of studies meeting the criteria were reviewed by OB and RQ. Any disagreements regarding
124 article inclusion were resolved after discussing with the senior reviewer (DS).

125 **Data extraction**

126 Two authors (HT and OB) extracted data simultaneously into a standard data extraction sheet. The data collected
127 included in-hospital overall mortality, post-discharge overall mortality, major adverse cardiovascular events
128 (MACE) acute heart failure, cardiogenic shock, LVEF (%), recurrent MI, and recurrent SCAD which predominantly
129 included recurrent de novo SCAD. Post-discharge mortality was defined as mortality after hospital discharge over
130 follow-up period. Cardiac arrest either on presentation (including out-of-hospital cardiac arrest) or index in-hospital
131 cardiac arrest was considered. In-hospital and long-term recurrent MI and SCAD on follow-up were included. Any
132 discrepancies were resolved after consulting the senior reviewer (DS).

133 **Assessment of methodological quality and risk of bias**

134 The reviewers then assessed the risk of bias for each study using the Newcastle-Ottawa Scale (NOS) for prospective
135 and retrospective cohort studies, and adapted NOS for studies without control arm (Total score is 6). The NOS rates

136 observational cohort studies based on the selection of participants, comparability between the exposed and
137 unexposed groups, and the assessment of the association between exposure and outcome. Studies with a score <5 are
138 considered to be of low quality. All included studies scored ≥ 5 . (**Supplementary material**)

139 **Statistical analysis**

140 Data were extracted, and the results were presented as risk ratio (RR) and pooled percentage. For single-arm meta-
141 analysis; we applied the formula: $SE = \sqrt{p(1-p)/n}$, where p stands for prevalence to calculate SE. Heterogeneity was
142 assessed using the I^2 test, which calculates percentage variability in endpoints that is due to heterogeneity rather than
143 to chance. The larger the I^2 , the more likely that any observed statistical outcomes are due to heterogeneity. An I^2
144 <30% for an outcome of interest was set as the standard for low heterogeneity. All statistical tests were 2-sided, and
145 a P -value <0.05 was considered statistically significant. We used the random-effects model in the presence of
146 significant heterogeneity ($p < 0.1$). The statistical analysis was performed using RevMan 5.4. The primary outcome
147 of our study was to compare in-hospital overall mortality between SCAD patients with and without CA. Secondary
148 outcomes of interest included post-discharge overall mortality, acute heart failure, cardiogenic shock, recurrent MI,
149 recurrent SCAD, and $LVEF \leq 40\%$. Finally, to assess for publication bias, we constructed funnel plots to assess
150 asymmetry for each effect estimate and Egger's test as a statistical test of funnel plot asymmetry. (**Supplementary**
151 **material**)


152 **Results**

153 **Search results and study characteristics**

154 A total of 269 non-duplicate study abstracts and titles were screened. Following the pre-defined exclusion and
155 inclusion criteria, 10 studies were selected for inclusion (**Figure 1**)^{5,9,11-17}. Detailed study characteristics are outlined
156 in **Table 1**. Out of 10 included studies, two were prospective^{13,15}, and eight were retrospective^{5,9,12,14,16-19}. The
157 studies represented various geographical regions, with four studies from the United States^{5,9,12,14,19}, two from
158 Canada^{13,15}, one from Switzerland¹¹, one from Italy¹⁷, one from Italy and Spain¹⁸, and one from the Middle East
159 (Kingdom of Saudi Arabia, United Arab Emirates, Kuwait, and Bahrain)¹⁶. A total of 3978 SCAD patients were
160 included, out of which 357 (9%) had concurrent CA. In addition to VT/VF, Giacobbe et al.¹⁸ and Phan et al.¹⁴
161 included PEA and asystole in their definition of cardiac arrest. Two studies reported CA on presentation, three

162 studies reported CA on presentation and during hospitalization, and five studies did not specify CA timing. Six
163 studies included SCAD confirmed by coronary imaging, including angiography. Daoulah et al. (51%), Krittanawong
164 et al (64%) and Tan et al. (78%) reported the lowest proportions of SCAD patients of female sex. Pooled patient
165 sample was predominantly of female sex and <65 years of age.

166



167

168 **Figure 1:** Flow diagram of literature search and selection of publications.

169

170

171

172

173

Table 1: Characteristics of included studies

Study	Type of Study	Definition of CA	Total no. of SCAD patients	Patients with CA (n, %)	CA on presentation (n, % of total CA)	Follow-up duration (months)	Duration of hospital stay (days)	Angiographic confirmation of SCAD? (Y/N)	Age (years)	Female n (%)	Defibrillator therapies	Defibrillator outcomes	SCAD type (% overall) ¶	Overall revascularization (n, %)
Giacobbe 2024 ¹⁸	Retrospective	PEA, asystole, VF, pulseless VT	375	20 (5)	6 (30) at presentation 14 (70) in-hospital	21 (10.7–46) (median)	7.5 ± 0.49	Y	52.6 ± 10.2	315 (84)	1 ICD 2 WCDs	-	Type 1: 23% Type 2: 50% Type 3: 6% Type 4: 26%	PCI: 130 (35%) CABG: 1 (0.2%)
Tan 2023 ¹²	Retrospective (NRD)	ICD-10 codes for VT and VF	877	118 (13)	Not specified	1	7.8 ± 8.3	N	52.6 ± 13.8	687 (78)	-	-	-	-
Antonutti 2021 ¹⁷	Retrospective	Sustained VT/VF	70	7 (10)	Not specified	39.1 (IQR 13.9 - 86.6) (median)	-	Y	52 (47-58)	60 (86)	-	-	Type 1: 56% Type 2: 43% Type 3: 1%	PCI: 13% CABG: 3%
Cheung 2020 ¹³	Prospective	Sustained VT/VF	1056	84 (8)	Not specified	57.6 ± 39.6 (mean)	-	Y	49.3 ± 11.3	941 (89)	8 ICDs	1 shock for VT/VF	-	Overall: 174 (16.5%)
Phan 2020 ¹⁴	Retrospective	Cardiac arrest, including PEA, asystole, VT/VF	208	11 (5)	Not specified	56.4 ± 37.2 (mean)	-	Y	48.53 ± 12.06	186 (94)	2 ICDs 1 WCD	0 shocks	-	PCI: 23 (11%) CABG: 9 (4.6%)
Krittawong 2020 ⁵	Retrospective	Not specified	375	20 (5)	Not specified	-	-	N	52.2 ± 12.8 (overall)	241 (64)	-	-	-	-
Daoulah 2020 ¹⁶	Retrospective	Sustained VT/VF	83	10 (12)	10 (100)	18.8 (IQR 9.0-40.1) (median)	-	Y	46 (26–81)	42 (51)	1 ICD	1 death confirmed 10 months post-discharge, unknown cause	Type 1: 52% Type 2: 42% Type 3: 4%	Overall: 60% PCI: 53% CABG: 7%
Chen 2020 ⁹	Retrospective	VT/VF	349	20 (6)	17 (85)	69.6 ± 54 (mean)	-	Not specified	47 ± 12	19 (95) for CA group	5 ICDs 4 WCDs	0 shocks	-	PCI: 7 (2%)
Saw 2017 ¹⁵	Prospective	VT/VF	327	29 (9)	29 (100)	37.2 (IQR 17.9 - 65.9) (median)	3 (IQR 2-5) (median)	Y	52.5 ± 9.6 (overall)	297 (91)	9 “cardioversion or ICD”	-	Type 1: 26% Type 2: 70% Type 3: 5%	Overall: 61 (18.7%) PCI: 16.5% CABG: 2.1%
Sharma 2017 ¹⁹	Retrospective	Not specified	102	14 (14)	7 (50) OOH 4 (29) in ED 3 (21) during/shortly after PCI	42 (mean)	-	Not specified	44 ± 11	88 (86)	7 ICDs 4 WCDs	1 shock for SVT	Not specified	PCI: 37 (36%) CABG: 3 (3%)

CA: Cardiac arrest, NRD: National Readmissions Database, OOH: Out of hospital, ED: Emergency department, PCI: percutaneous coronary intervention, SVT: Supraventricular tachycardia

* Data cited is for SCAD patients with CA unless specified otherwise

¶ Saw J. Coronary angiogram classification of spontaneous coronary artery dissection. *Catheter Cardiovasc Interv.* 2014;84(7):1115-1122.


174 **Clinical outcomes**

175 A single-arm meta-analysis was performed to assess the prevalence of study endpoints among SCAD patients with
 176 concurrent CA. A pooled analysis revealed that in-hospital mortality, post-discharge mortality, recurrent MI and
 177 recurrent SCAD occurred in 20%, 3%, 12% and 9% of SCAD patients with CA, respectively. (**Figure 2**). Out of a
 178 pooled 24 ICDs and 11 WCDs, there was only one appropriate ICD discharge reported for VT/VF, and one
 179 inappropriate ICD discharge for supraventricular tachycardia (SVT) (**Table 1**).

180


181 **Figure 2:**

182 **A. In-hospital mortality**




183

184 **B. Post-discharge mortality**




185

186 **C. Recurrent MI**



187

188 D. Recurrent SCAD



189

190 Outcomes among SCAD patients with CA compared to SCAD patients without CA

191

192 In-hospital overall mortality:

193 Seven studies were included in the meta-analysis and the pooled results showed that SCAD patients with CA had
 194 higher in-hospital overall mortality compared to SCAD patients without CA (27/295 vs 47/2900, RR = 6.75, 95% CI
 195 [4.50, 10.14], P < 0.00001, I² = 0%). (Figure 3A)

196

197 Post-discharge overall mortality:

198 Four studies were included in the meta-analysis. Follow-up ranged from 18.8 to 39.1 months for studies reporting
 199 median follow-up and 42.0 to 69.6 months for studies reporting mean follow-up. NRD-based study by Tan et al.
 200 assessed 1-month post-discharge outcomes. The pooled results showed that SCAD patients with CA had higher
 201 post-discharge overall mortality compared to SCAD patients without CA (3/127 vs 7/1488, RR = 5.86, 95% CI
 202 [1.72, 19.91], P = 0.005, I² = 0%). (Figure 3B)

203

204 Major adverse cardiovascular events (MACE)

205 Four studies were included in the meta-analysis and the pooled results showed that SCAD patients with CA had
206 higher risk of MACE compared to SCAD patients without CA (29/121 vs 180/1463, RR = 1.91, 95% CI [1.11, 3.27],
207 $P=0.02$, $I^2=77\%$). High heterogeneity was noted, potentially attributable to varying definitions of MACE across
208 studies. (Figure 3C)

209

210 **Acute heart failure:**

211 Three studies were included in the meta-analysis and the pooled results showed that SCAD patients with CA had
212 higher risk of acute heart failure compared to SCAD patients without CA (34/212 vs 49/1804, RR = 4.82, 95% CI
213 [3.22, 7.20], $P < 0.00001$) ($I^2= 42\%$). (Figure 3D)

214

215 **Cardiogenic shock:**

216 Two studies were included, and the pooled results showed that SCAD patients with CA had higher risk of
217 cardiogenic shock compared to SCAD patients without CA (37/128 vs 39/832, RR = 6.11, 95% CI [4.07, 9.19],
218 $P < 0.00001$) ($I^2= 64\%$). (Figure 3E)

219

220 **Recurrent MI**

221 Three studies were included, and the pooled results showed that SCAD patients with CA had higher risk of recurrent
222 MI compared to SCAD patients without CA (16/114 vs 134/1400, RR =3.31, 95% CI [2.03, 5.39], $P < 0.00001$),
223 $I^2=56\%$) (Figure 3F)

224

225 **Recurrent SCAD**

226 Recurrent SCAD primarily included recurrent de novo SCAD, and not SCAD extension. Five studies were included,
227 and the pooled results showed no significant difference in SCAD recurrence between SCAD patients with CA
228 compared to SCAD patients without CA (14/135 vs 84/1551, RR = 2.48, 95% CI [0.59, 10.47], $P = 0.22$) ($I^2= 65\%$).
229 (Figure 3G)

230


231 **LVEF \leq 40%**

232 Three studies were included, and the pooled results showed that SCAD patients with CA had higher risk of LVEF \leq
 233 40% compared to SCAD patients without CA (20/105 vs 52/1242, RR = 5.26, 95% CI [2.78, 9.94], $P < 0.00001$) ($I^2 =$
 234 0%). (Figure 3H)

235


236 **Figure 3:**

237 **A. In-hospital overall mortality**




238

239 **B. Post-discharge overall mortality**



240

241 **C. Major adverse cardiovascular event (MACE)**




242

243

244 **D. Acute Heart Failure**


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

245



246 **E. Cardiogenic Shock**

247



248

249 **F. Recurrent MI**


250



251

252 **G. Recurrent SCAD**

253




254

255

256 **H. LVEF ≤ 40%**

257



258

259

260

261

262

263 Discussion

264 We present, to the best of our knowledge, the largest analysis on the clinical outcomes in SCAD with concurrent
 265 cardiac arrest. Patients with SCAD and CA were at a higher risk of in-hospital and post-discharge mortality, acute
 266 heart failure, cardiogenic shock, recurrent MI and recurrent SCAD. Importantly, our results are mostly applicable to
 267 SCAD patients with CA who survive at least up to hospital arrival to undergo medical evaluation and additional
 268 testing. Those who do not survive to hospital presentation may have unique clinical characteristics and risk factors
 269 that are likely largely understudied.

270 Although SCAD is generally associated with good long-term outcomes with low overall mortality and incidence of
 271 MACE⁴, our pooled double-arm meta-analysis highlights that patients who develop concurrent CA be considered
 272 high-risk for both acute and long-term complications. Nevertheless, cause-specific mortality in these patients is not
 273 well explored. Patients with SCAD and CA are more likely to present with STEMI, which is commonly associated
 274 with larger infarct size and increased risk of LV dysfunction and adverse cardiovascular outcomes⁹. Krittanawong
 275 et al. reported that atrial fibrillation, steroid use, ventricular arrhythmias, and cardiac arrest were independent
 276 predictors of in-hospital mortality in SCAD patients⁵. Conservative management at index presentation is typically
 277 pursued, although Waterbury et al. highlighted that 17.5% of conservatively managed SCAD patients had early

278 SCAD progression based on angiographic evaluation; specifically, patients with intramural hematoma at baseline
279 were at higher risk of progression and early deterioration ^{20,21} .

280 Studies on the community-based Canadian SCAD cohort ⁴ , the Nationwide Readmissions Database ¹² , the Mayo
281 Clinic SCAD Virtual Multi-Center registry ²² , and a multinational study covering four Gulf countries (KSA, UAE,
282 Kuwait, and Bahrain) ¹⁶ have recorded rates of CA between ~3-13% at index hospitalization and ~4% of patients
283 during post-discharge follow-up, corresponding with our pooled estimates. The reported prevalence of CA in SCAD
284 patients is more variable, which could be explained by a multitude of reasons, including baseline patient features and
285 SCAD severity, and time frame over which CA was assessed (e.g., immediate post-event, in-hospital, and long-term
286 follow-up).

287 Management recommendations for SCAD are based on observational studies, and there are no published
288 randomized control trials yet. Consensus statements by the European Society of Cardiology (ESC) and American
289 Heart Association (AHA) on SCAD recommend medical management when possible for SCAD patients who are
290 hemodynamically stable and do not show signs of ongoing myocardial ischemia ^{2,23} . Long-term management of
291 SCAD involves maintenance on aspirin and beta-blockers, the latter associated with reduced incidence of SCAD
292 recurrence in one observational study ¹⁵ . This guidance is based on findings that the dissection will most likely heal
293 spontaneously, and recurrence typically does not involve the initial culprit coronary artery, nor does PCI prevent
294 future SCAD recurrence ^{21,24} . In our meta-analysis, only three studies had data on beta-blocker usage, although
295 specific data on SCAD patients with concurrent CA was lacking, and use of antiarrhythmic medications was
296 unavailable ^{11,15,17} . In a prospective, multicenter study by Saw et al. of 750 SCAD patients out of whom 8.3% had
297 VT/VF, aspirin and beta-blocker usage was high with low long-term mortality ⁴ . Tweet et al. reported an
298 uncomplicated hospital course among 31 SCAD patients managed conservatively, with two deaths occurring on
299 long-term follow-up. In contrast, failure rate of PCI was 53% and it did not significantly reduce rates of
300 revascularization and recurrence of SCAD ²⁴ . One population very much underrepresented in the included studies is
301 obstetric patients; pregnancy and the peri-partum period have been posited as major risk factors for SCAD in
302 multiple studies with a more severe presentation ²⁵ . Among 13 deaths attributable to pregnancy-associated SCAD
303 (P-SCAD) in the MBRRACE-UK audit, 12 suffered from an out-of-hospital CA ²⁶ . Phan et al. found that SCAD
304 patients with CA were more likely to have P-SCAD ¹⁴ . However, Krittanawong et al. in their analysis based on NRD

305 data noted a similar incidence of CA between P-SCAD and non-P-SCAD²⁷. Therefore, further research is needed to
306 clarify possible risk-enhancing factors for CA and CA-related outcomes in this patient group.

307 Those who receive PCI show no statistical difference in long-term outcomes compared to those who received no
308 PCI, and the former may expose patients to greater risks of iatrogenic complications such as propagation of
309 intramural hematoma and dissection and abrupt vessel occlusion^{4,24,28,29}. This can lead to an increased myocardial
310 ischemic burden and subsequently increased risk of ventricular arrhythmogenicity. Nearly half of the VT/VF arrests
311 reported in their cohort by Phan et al. occurred during PCI¹⁴. A meta-analysis by Bocchino *et al.* also showed that
312 the mean success rate of PCI was less than 50% and that revascularization therapies did not decrease rates of all-
313 cause mortality, cardiovascular mortality, myocardial infarction, heart failure, and SCAD recurrence³⁰. In light of
314 uncertain benefits and increased risk of bleeding complications associated with antiplatelet therapy in SCAD
315 patients who do not undergo PCI, experts recommend individualized decision-making considering the risk-benefit
316 ratio². Indications for the use of more advanced imaging modalities like intravascular ultrasound (IVUS) and optical
317 coherence tomography (OCT) are also not well defined but may optimize the use of PCI in high-risk patients,
318 though their uptake in studies has been low^{30,31}.

319 Notably, based on our pooled sample which included placement of 24 ICDs and 11 WCDs, there was only one
320 appropriate ICD discharge reported for VT/VF by Cheung et al. over a mean follow-up of 4.8 ± 3.3 years, and one
321 inappropriate discharge for SVT^{13, 19}. In a community-based study of 27 patients with VA due to SCAD, Chen *et al.*
322 demonstrated that no patient developed recurrent VA due to SCAD and none required defibrillation therapies over a
323 5.8-year mean follow-up⁹. Over a mean follow up period of 3.5 years following ICD placement among seven
324 SCAD patients with SCD as part of the MGH-SCAD registry, there was one inappropriate ICD discharge for
325 supraventricular tachycardia¹⁹. The unclear risk-benefit ratio of ICD placement for secondary SCD prevention in
326 SCAD was highlighted by Garg et al in their meta-analysis, noting 1.2% (95% CI: 0%–15.8%, I2 = 0%) and 1%
327 (95% CI: 0%–15.3%, I2 = 0%) patients received appropriate and inappropriate ICD therapies, respectively, during
328 the follow-up period³². Given these findings and considering that most SCAD lesions heal spontaneously on follow-
329 up, current guidelines do not support early ICD implantation for patients after an episode of cardiac arrest with a
330 reversible cause^{33,34}. Our results support the idea of SCAD-mediated CA being a transient substrate with a low
331 recurrent event rate, as long as the LVEF recovers. Factors such as incomplete coronary revascularization,

332 persistently reduced LVEF, and recurrent VA can also be used to risk-stratify sudden cardiac death and guide
333 decision-making regarding ICD placement³⁵. It would be of value for future studies to stratify patient outcomes data
334 based on timing of CA – such as out-of-hospital, in-hospital and procedural. Data remains scarce on use of multi-
335 modality imaging for determining ICF placement, optimal timing of ICD placement, long-term appropriateness of
336 ICD therapies in this patient population and role of WCDs as a bridge to ICD implantation, and further research is
337 needed.

338 We also found that the incidence of recurrent de novo SCAD was higher in SCAD patients with CA. Management
339 of modifiable factors such as smoking cessation, avoidance of pregnancy, and adherence to long-term medical
340 therapy with beta-blockers may decrease the risk of recurrent SCAD. The development of VA in SCAD patients can
341 be related to multiple factors, with only one of them being recurrent SCAD. For instance, myocardial fibrosis after
342 SCAD-induced MI may also increase the long-term risk of VAs. Hence, future studies evaluating the association
343 between myocardial fibrosis as assessed by imaging techniques such as cardiac MRI (CMR) and recurrent VAs may
344 reveal new strategies for identifying candidates that may benefit from ICD placement.

345 Indeed, it is well recognized that solely relying on LVEF is inadequate in stratifying SCAD patients' future risk of
346 SCD; the cut-off of LVEF < 35% that guides ICD placement may correctly predict only ~20% of SCD events in
347 other cardiomyopathies³⁶. CMR—particularly late gadolinium enhancement (LGE) to detect myocardial fibrosis—
348 provides additional prognostic information about SCD risk over solely LVEF³⁷⁻³⁹. Replacement of viable
349 myocardial tissue by fibrosis in SCAD is likely to significantly enhance risk of post-SCAD arrhythmias. Hence,
350 characterizing such an arrhythmogenic substrate by CMR-LGE may enhance SCD risk stratification and further
351 guide appropriateness of ICD implantation. In this context, one study of 14 patients with acute or recurrent SCAD
352 demonstrated LGE in the distribution of the culprit coronary artery in all cases⁴⁰. This finding needs to be replicated
353 in larger cohorts. Patient populations who would benefit most from CMR-based characterization of scar tissue
354 require further defining. For instance, Androulakis *et al.* demonstrated that SCAD involving the RCA was predictive
355 of myocardial fibrosis detected by LGE (OR = 5.2; p = 0.034)⁴¹. Additionally, most patients with SCAD may not
356 present with large infarct sizes and subsequent myocardial fibrosis; however, those with pregnancy-related SCAD,
357 multi-vessel SCAD, STEMI, CA, extracoronary arteriopathies (*e.g.*, fibromuscular dysplasia, focal stenoses, and

358 arterial tortuosity) are more likely to present with larger infarct sizes and may therefore benefit from further
359 anatomical and functional characterization by CMR and LGE ^{41,42}.

360 **Limitations**

361 All included studies were observational in nature, with results impacted by the completeness of collected and
362 analyzed data. Tan et al. was a database study utilizing the National Readmissions Database and used ICD coding
363 for coronary artery dissection due to lack of specific ICD-10 codes for SCAD, possibly contributing to heterogeneity
364 of studied patients due to potential inclusion of iatrogenic coronary artery dissection and atherosclerotic coronary
365 artery dissection. Similarly, Krittanawong et al. was an ICD-9 or -10 codes-based study without angiogram
366 confirmation which may contribute to heterogeneity. These studies had a higher proportion of men, suggesting that
367 some of the patients may have had dissection in the setting of atherosclerosis. As our study was a systematic review
368 and meta-analyses of published observational studies, some results may be hindered by publication biases.
369 Heterogeneity was noted among several variables, which can be attributed to differences in study populations,
370 definitions of endpoints, and other clinical and/or procedural variables. Differences in population characteristics,
371 interventions, and outcomes measured can create discrepancies that make it challenging to draw generalized
372 conclusions. Similarly, these cohorts only included patients who survived long enough to be diagnosed with SCAD
373 and did not include autopsy data. SCAD is a particularly important clinical entity among obstetric patients, although
374 our review noted data on this patient group to be lacking and so was literature on sex-based differences in outcomes.
375 Further research is needed to explore outcomes in women and obstetric patients with SCAD and CA. Due to
376 limitations in the reported literature, our study did not focus on sex-based differences or pregnancy associated
377 SCAD. Although our study is, to the best of our knowledge, the largest to study clinical outcomes in SCAD patients
378 with CA, it is important to acknowledge that these findings are hypothesis-generating and may not be powered
379 sufficiently to guide clinical care in a diverse patient population with varying characteristics and risk factors.

380

381 **Conclusions**

382 Our systematic review and meta-analyses highlight that concurrent CA in SCAD is associated with worse in-hospital
383 and post-discharge mortality, and higher risk of acute heart failure, cardiogenic shock, recurrent MI and recurrent

384 SCAD. Pooled follow-up ICD and WCD data noted a low recurrent CA event rate. Our findings support SCAD-
385 mediated CA to be a transient substrate, supporting a conservative approach to secondary CA prevention in SCAD
386 consistent with the current recommendation for atherosclerotic CAD/MI-mediated CA. Further research is needed
387 on various aspects of management relevant to this high-risk patient population, including patient selection for ICD
388 placement and the role of WCDs in managing early recurrent SCD.

389

390

391

392 **References**

393

- 394 1. Tweet MS, Hayes SN, Pitta SR et al. Clinical features, management, and prognosis of spontaneous
395 coronary artery dissection. *Circulation* 2012;126:579-88.
- 396 2. Hayes SN, Kim ESH, Saw J et al. Spontaneous Coronary Artery Dissection: Current State of the Science:
397 A Scientific Statement From the American Heart Association. *Circulation* 2018;137:e523-e557.
- 398 3. Saw J, Starovoytov A, Humphries K et al. Canadian spontaneous coronary artery dissection cohort study:
399 in-hospital and 30-day outcomes. *Eur Heart J* 2019;40:1188-1197.
- 400 4. Saw J, Starovoytov A, Aymong E et al. Canadian Spontaneous Coronary Artery Dissection Cohort Study.
401 *Journal of the American College of Cardiology* 2022;80:1585-1597.
- 402 5. Krittanawong C, Kumar A, Wang Z et al. Clinical features and prognosis of patients with spontaneous
403 coronary artery dissection. *Int J Cardiol* 2020;312:33-36.
- 404 6. Stanojevic D, Apostolovic S, Kostic T et al. A review of the risk and precipitating factors for spontaneous
405 coronary artery dissection. *Front Cardiovasc Med* 2023;10:1273301.
- 406 7. Saw J, Aymong E, Mancini GB, Sedlak T, Starovoytov A, Ricci D. Nonatherosclerotic coronary artery
407 disease in young women. *Can J Cardiol* 2014;30:814-9.
- 408 8. García-Guimarães M, Sanz-Ruiz R, Sabaté M et al. Spontaneous coronary artery dissection and ST-
409 segment elevation myocardial infarction: Does clinical presentation matter? *Int J Cardiol* 2023;373:1-6.

- 410 9. Chen S, Ambrosy AP, Mahrer KN, Lundstrom RJ, Naderi S. Spontaneous Coronary Artery Dissection and
411 Incident Ventricular Arrhythmias: Frequency, Clinical Characteristics, and Outcomes. *JACC Cardiovasc*
412 *Interv* 2020;13:539-541.
- 413 10. Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for
414 reporting systematic reviews. *Bmj* 2021;372:n71.
- 415 11. Würdinger M, Schweiger V, Gilhofer T et al. Twenty-five-year trends in incidence, angiographic
416 appearance, and management of spontaneous coronary artery dissection. *Int J Cardiol* 2024;395:131429.
- 417 12. Tan MC, Yeo YH, Ang QX et al. Hospital Outcomes of Spontaneous Coronary Artery Dissection With
418 Concurrent Ventricular Arrhythmias. *Journal of the Society for Cardiovascular Angiography &*
419 *Interventions* 2024;3:101231.
- 420 13. Cheung CC, Starovoytov A, Parsa A et al. In-hospital and long-term outcomes among patients with
421 spontaneous coronary artery dissection presenting with ventricular tachycardia/fibrillation. *Heart Rhythm*
422 2020;17:1864-1869.
- 423 14. Phan D, Clare R, Duan L, Kim C, Moore N, Lee M-S. Characteristics and outcomes of patients with
424 spontaneous coronary artery dissection who suffered sudden cardiac arrest. *Journal of Interventional*
425 *Cardiac Electrophysiology* 2021;60:77-83.
- 426 15. Saw J, Humphries K, Aymong E et al. Spontaneous Coronary Artery Dissection: Clinical Outcomes and
427 Risk of Recurrence. *J Am Coll Cardiol* 2017;70:1148-1158.
- 428 16. Daoulah A, Al-Faifi SM, Alsheikh-Ali AA, Hersi AS, Lotfi A. Ventricular Arrhythmias in Patients with
429 Spontaneous Coronary Artery Dissection: Findings from the Gulf Spontaneous Coronary Artery Dissection
430 (Gulf SCAD) Registry. *Crit Pathw Cardiol* 2020;19:146-152.
- 431 17. Antonutti M, Baldan F, Lanera C et al. Spontaneous coronary artery dissection: Role of prognostic markers
432 and relationship with genetic analysis. *International Journal of Cardiology* 2021;326:19-29.
- 433 18. Giacobbe F, Bruno F, Brero M et al. Spontaneous coronary artery dissection (SCAD) with cardiac arrest at
434 presentation: A subanalysis from the DISCO registry. *Int J Cardiol* 2024;412:132331.
- 435 19. Sharma S, Rozen G, Duran J, Mela T, Wood MJ. Sudden Cardiac Death in Patients With Spontaneous
436 Coronary Artery Dissection. *Journal of the American College of Cardiology* 2017;70:114-115.

- 437 20. Waterbury TM, Tweet MS, Hayes SN et al. Early Natural History of Spontaneous Coronary Artery
438 Dissection. *Circ Cardiovasc Interv* 2018;11:e006772.
- 439 21. Hassan S, Prakash R, Starovoytov A, Saw J. Natural History of Spontaneous Coronary Artery Dissection
440 With Spontaneous Angiographic Healing. *JACC Cardiovasc Interv* 2019;12:518-527.
- 441 22. Kok SN, Hayes SN, Cutrer FM et al. Prevalence and Clinical Factors of Migraine in Patients With
442 Spontaneous Coronary Artery Dissection. *J Am Heart Assoc* 2018;7:e010140.
- 443 23. Adlam D, Alfonso F, Maas A, Vrints C, Writing C. European Society of Cardiology, acute cardiovascular
444 care association, SCAD study group: a position paper on spontaneous coronary artery dissection. *European*
445 *Heart Journal* 2018;39:3353-3368.
- 446 24. Tweet MS, Eleid MF, Best PJ et al. Spontaneous coronary artery dissection: revascularization versus
447 conservative therapy. *Circ Cardiovasc Interv* 2014;7:777-86.
- 448 25. Tweet MS, Hayes SN, Codosi E, Gulati R, Rose CH, Best PJM. Spontaneous Coronary Artery Dissection
449 Associated With Pregnancy. *Journal of the American College of Cardiology* 2017;70:426-435.
- 450 26. Knight M, Tuffnell D. A View From the UK: The UK and Ireland Confidential Enquiry into Maternal
451 Deaths and Morbidity. *Clin Obstet Gynecol* 2018;61:347-358.
- 452 27. Krittanawong C, Patel N, Bandyopadhyay D et al. Spontaneous coronary artery dissection outcomes among
453 pregnant vs. non-pregnant women. *Eur Heart J Acute Cardiovasc Care* 2024;13:423-428.
- 454 28. Hayes SN, Tweet MS, Adlam D et al. Spontaneous Coronary Artery Dissection: JACC State-of-the-Art
455 Review. *Journal of the American College of Cardiology* 2020;76:961-984.
- 456 29. Prakash R, Starovoytov A, Heydari M, Mancini GB, Saw J. Catheter-Induced Iatrogenic Coronary
457 Artery Dissection in Patients With Spontaneous Coronary Artery Dissection. *JACC Cardiovasc Interv*
458 2016;9:1851-3.
- 459 30. Bocchino PP, Angelini F, Franchin L et al. Invasive versus conservative management in spontaneous
460 coronary artery dissection: A meta-analysis and meta-regression study. *Hellenic J Cardiol* 2021;62:297-
461 303.
- 462 31. Paulo M, Sandoval J, Lennie V et al. Combined use of OCT and IVUS in spontaneous coronary artery
463 dissection. *JACC Cardiovasc Imaging* 2013;6:830-2.

- 464 32. Garg J, Shah K, Shah S, Turagam MK, Natale A, Lakkireddy D. Implantable cardioverter-defibrillator in
465 patients with spontaneous coronary artery dissection presenting with sudden cardiac arrest. *J Cardiovasc*
466 *Electrophysiol* 2021;32:2595-2600.
- 467 33. Russo Andrea M, Poole Jeanne E. Secondary Prevention. *JACC: Clinical Electrophysiology* 2017;3:29-32.
- 468 34. Al-Khatib SM, Stevenson WG, Ackerman MJ et al. 2017 AHA/ACC/HRS Guideline for Management of
469 Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the
470 American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
471 and the Heart Rhythm Society. *J Am Coll Cardiol* 2018;72:e91-e220.
- 472 35. Ragupathi L, Pavri BB. Tools for risk stratification of sudden cardiac death: a review of the literature in
473 different patient populations. *Indian Heart J* 2014;66 Suppl 1:S71-81.
- 474 36. Wellens HJ, Schwartz PJ, Lindemans FW et al. Risk stratification for sudden cardiac death: current status
475 and challenges for the future. *Eur Heart J* 2014;35:1642-51.
- 476 37. Halliday BP, Gulati A, Ali A et al. Association Between Midwall Late Gadolinium Enhancement and
477 Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular
478 Systolic Dysfunction. *Circulation* 2017;135:2106-2115.
- 479 38. Di Marco A, Anguera I, Schmitt M et al. Late Gadolinium Enhancement and the Risk for Ventricular
480 Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. *JACC*
481 *Heart Fail* 2017;5:28-38.
- 482 39. Li S, Wang Y, Yang W et al. Cardiac MRI Risk Stratification for Dilated Cardiomyopathy with Left
483 Ventricular Ejection Fraction of 35% or Higher. *Radiology* 2023;306:e213059.
- 484 40. Chandrasekhar J, Thakkar J, Starovoytov A, Mayo J, Saw J. Characteristics of spontaneous coronary artery
485 dissection on cardiac magnetic resonance imaging. *Cardiovasc Diagn Ther* 2020;10:636-638.
- 486 41. Androulakis E, Azzu A, Papagkikas P et al. Spontaneous Coronary Artery Dissection: Insights From
487 Cardiac Magnetic Resonance and Extracoronary Arterial Screening. *Circulation* 2022;145:555-557.
- 488 42. Al-Hussaini A, Abdelaty A, Gulsin GS et al. Chronic infarct size after spontaneous coronary artery
489 dissection: implications for pathophysiology and clinical management. *Eur Heart J* 2020;41:2197-2205.

490

491 **Supplementary material**

492

493 **Supplementary table 1:** Quality assessment of included studies using adapted Newcastle-

494 Ottawa Scale (NOS)

Study	Selection	Comparability	Outcome	Total score
Giacobbe et al. 2024	3	1	3	6
Antonutti et al. 2021	3	-	3	6
Tan et al. 2023	3	1	3	7
Cheung et al. 2020	4	0	3	7
Krittanawong et al. 2020	4	0	1	5
Phan et al. 2020	4	1	2	7
Saw et al. 2017	3	-	2	5
Chen et al. 2020	3	-	2	5
Daoulah et al. 2020	3	1	2	6
Sharma et al. 2017	3	1	2	6

495

496

497 **Supplementary Figure 2:** Publication bias for the outcomes of SCAD with CA vs SCAD without CA:

498 (A) In hospital overall mortality, (B) Post-discharge overall mortality, (C) Acute heart failure, (D)

499 Cardiogenic shock, (E) MACE (F) Recurrent MI, (G) Recurrent SCAD, (H) LVEF \leq 40%


500

501

(A)

502


503



504

505


(B)



506

507


(C)



508

509


(D)



510

511


(E)



512

513

(F)




514

515

516

(G)

517




518

519

520

(H)




521

522

523

SCAD with concurrent cardiac arrest (CA)

(N= 3978; 357 [9%] with CA)



20% In-hospital mortality

3% Post-discharge mortality

12% Recurrent MI

9% Recurrent SCAD


Compared to SCAD without CA

↑ In-hospital mortality
(RR 6.7)

↑ Post-discharge mortality
(RR 5.9)

↑ Recurrent MI
(RR 3.3)

↑ Recurrent SCAD
(RR 1.9)



24 
ICDs

11 
WCDs



1 appropriate (VT/VF)

1 inappropriate (SVT)